Abstract
Target Audience and Goal Statement
This educational activity is intended for an audience of healthcare professionals in the Asia-Pacific region, specifically rheumatologists, dermatologists, gastroenterologists, and other healthcare providers involved in the treatment of patients with chronic inflammatory diseases.
The goal of this activity is to increase knowledge about the clinical development process and regulatory framework for biosimilars as well as potential issues to consider when choosing originator or biosimilar products for the treatment of chronic inflammatory diseases.
Upon completion of this activity, participants will be able to:
Describe what biosimilar products are and the technology behind them compared with original biologic products
Discuss the clinical data required to approve original biologic and biosimilar products
Describe the regulatory framework for biosimilars in the United States, Europe, Japan, Canada, and Australia
Outline potential issues to consider when choosing originator or biosimilar products to optimize care of patients with chronic inflammatory diseases
This educational activity is intended for an audience of healthcare professionals in the Asia-Pacific region, specifically rheumatologists, dermatologists, gastroenterologists, and other healthcare providers involved in the treatment of patients with chronic inflammatory diseases.
The goal of this activity is to increase knowledge about the clinical development process and regulatory framework for biosimilars as well as potential issues to consider when choosing originator or biosimilar products for the treatment of chronic inflammatory diseases.
Upon completion of this activity, participants will be able to:
Describe what biosimilar products are and the technology behind them compared with original biologic products
Discuss the clinical data required to approve original biologic and biosimilar products
Describe the regulatory framework for biosimilars in the United States, Europe, Japan, Canada, and Australia
Outline potential issues to consider when choosing originator or biosimilar products to optimize care of patients with chronic inflammatory diseases
| Original language | English |
|---|---|
| Type | CPD Educational activity |
| Media of output | Online |
| Publisher | Medscape Education |
| Number of pages | 7 |
| Publication status | Published - 1 Jul 2015 |
Keywords
- Biosimilars
- biologic agents
- Small-Molecule Drugs
- CPD